Management of endogenous cryptococcal endophthalmitis with voriconazole

Canadian Journal of Ophthalmology

Volumn 44, Issue 6, 2009, Pages

  Vela, José I ^a,b   Díaz Cascajosa, Jesús ^a   Sanchez, Ferran ^a   Roselló, Noemí ^a   Buil, José A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Institut Condal d Oftalmologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; VORICONAZOLE;

AGED; ANTIBIOTIC THERAPY; CASE REPORT; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ENDOPHTHALMITIS; FEMALE; HUMAN; LETTER; RECURRENT INFECTION; SLIT LAMP; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL IMPAIRMENT;

EID: 72849116080     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-153     Document Type: Letter

References (5)

1. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008;92:871-878 (Pubitemid 351969658)
2. Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: case report and review. Clin Infect Dis 1992;14:1069-1073
3. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:2014-2020
4. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-47 (Pubitemid 38063603)
5. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009;29:362-370